Recce Pharmaceuticals Ltd (ASX:RCE)

Market Cap	169.17M +65.8%
Revenue (ttm)	7.51M +49.3%
Net Income	-21.43M
EPS	-0.09
Shares Out	289.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,232
Average Volume	87,777
Open	0.5850
Previous Close	0.5850
Day's Range	0.5750 - 0.5900
52-Week Range	0.2750 - 0.7300
Beta	0.21
RSI	44.00
Earnings Date	Feb 27, 2026

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infect...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RCE

Financial Performance

In fiscal year 2025, Recce Pharmaceuticals's revenue was 7.51 million, an increase of 49.33% compared to the previous year's 5.03 million. Losses were -21.43 million, 21.3% more than in 2024.